New trial matches Kids' cancers to targeted drugs
NCT ID NCT06208657
First seen Dec 15, 2025 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that target their specific tumor's genetic changes can help. About 90 participants will receive one of four drug combinations based on their tumor profile. The goal is to find safe doses and see if tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
BC Children's Hospital
RECRUITINGVancouver, Canada
Contact Email: •••••@•••••
-
CHU Sainte Justine
RECRUITINGMontreal, Canada
Contact Email: •••••@•••••
-
Children's Hospital of Eastern Ontario
NOT_YET_RECRUITINGOttawa, Canada
Contact Email: •••••@•••••
-
John Hunter Children's Hospital
RECRUITINGNewcastle, New South Wales, Australia
Contact Email: •••••@•••••
-
Monash Children's Hospital
RECRUITINGMelbourne, Victoria, Australia
Contact Email: •••••@•••••
-
Perth Children's Hospital
RECRUITINGPerth, Western Australia, Australia
Contact Email: •••••@•••••
-
Queensland Children's Hospital
RECRUITINGBrisbane, Queensland, Australia
Contact Email: •••••@•••••
-
Royal Hobart Hospital
RECRUITINGHobart, Tasmania, 7000, Australia
Contact Email: •••••@•••••
-
Stollery Children's Hospital
NOT_YET_RECRUITINGEdmonton, Canada
Contact Email: •••••@•••••
-
Sydney Children's Hospital, Randwick
RECRUITINGSydney, New South Wales, Australia
Contact Email: •••••@•••••
-
The Children's Hospital at Westmead
RECRUITINGSydney, New South Wales, Australia
Contact Email: •••••@•••••
-
The Hospital for Sick Children
RECRUITINGToronto, Canada
Contact Email: •••••@•••••
-
The Royal Children's Hospital
RECRUITINGMelbourne, Victoria, Australia
Contact Email: •••••@•••••
-
Women's and Children's Hospital
RECRUITINGAdelaide, South Australia, Australia
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paxalisib, Opdualag (nivolumab + relatlimab), irinotecan, temozolomide
What this could lead to
If successful, this could lead to more effective, personalized treatments for children with hard-to-treat cancers by matching drugs to their tumor's genetic profile.
What could go wrong
This is an early-phase trial with only 90 participants, so results may not apply to all children. The drugs may cause side effects or not shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.